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Objectives: Although phthalates like dibutyl phthalate (DBP) and di-2-ethylhexyl phthalate (DEHP) are commonly used as plasti-
cizers and their metabolites are especially suspected of reproductive toxicity, little is known about occupational exposure to those 
phthalates. The aim of this study was to assess the utility of measuring the metabolite concentrations of DBP and DEHP in serum 
and urine samples as an indicator of occupational exposure to those phthalates.
Methods: Phthalate metabolites were analyzed by using column-switching high-performance liquid chromatography tandem 
mass spectrometry (LC-MS/MS). 
Results: We detected phthalate metabolites in serum and urine matrices at approximately 10-fold lower than the limit of detec-
tion of those metabolites in the same matrix by LC-MS/MS without column switching, which was suffi cient to evaluate concentra-
tions of phthalate metabolites for industrial workers and the general population. 
Conclusion: The accuracy and precision of the analytical method indicate that urinary metabolite determination can be a more 
acceptable biomarker for studying phthalate exposure and adverse health outcomes.
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Introduction
Dibutyl phthalate (DBP) and di-2-ethylhexyl phthalate (DEHP) 
are industrial chemicals that can act as plasticizers that impart 
flexibility and resilience, and which are used in enormous 
quantities as plasticizers in polyvinyl chloride resins, nitrocellu-
lose lacquers, and elastomers. These phthalates also have been 
used as solvents for perfume, oils, textiles, lubricating agents, 
and safety glass [1,2]. As the phthalate plasticizers are not co-
valently bound to resins, they can leach, migrate, or evaporate 
into the workplace environment.
People can be exposed to these phthalates through in-
gestion, inhalation, and dermal exposure. Both a population 
study [3] and occupational studies [4,5] have indicated that the 
personal air sample levels of phthalates correlate modestly well 
with concentrations of  urinary metabolites. This implies that 
inhalation exposure is a more important route of exposure than 
oral and dermal exposure [6].
Toxicological studies on animals have demonstrated that 
several phthalates cause decreased testicular and epididymal 
weight, lessened testes, deterioration of semen quality, and de-
creased fertility index [7-9]. Some phthalates are also suspected 
human endocrine disruptors [10,11].
Studies on occupational exposure to DBP and DEHP 
so far are very limited [4,5,12]. Toxicological studies of these 
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phthalates have so far been researched extensively in experi-
mental animals. The American Conference of Governmental 
Industrial Hygienists has classified DBP as a substance that 
produces ocular and respiratory irritation, reproductive effects, 
testicular injury on the basis of findings from experimental ani-
mal studies, and has categorized DEHP as a confirmed animal 
carcinogen with unknown relevance to humans. 
Even though there are many analytical methods for the 
determination of  phthalates in water and air, including high 
performance liquid chromatography [14-16], analysis of phthal-
ates, such as DBP and DEHP, in various samples may present 
a difficult and serious problem because a higher background 
is often encountered. This is due to phthalate contamination 
in many laboratory products, plastic tubing, room air, etc. To 
overcome these contaminations during the analytical proce-
dure, the metabolites analysis of phthalates and column-switch-
ing techniques are preferable. The use of  column-switching 
techniques allows the entire extraction, including load, wash, 
and re-equilibration to be performed in a short time scale while 
the separation is in progress. This has the advantage of decreas-
ing the risk of contamination and analytical error. 
Generally, phthalates are metabolized and excreted and 
do not accumulate in the body [13]. Studies on biomarkers for 
the estimation of phthalate exposure in the general population 
have been performed using several analysis methods [14-16]. 
Recently, column-switching techniques have been combined 
with tandem mass spectrometry for successful biosample analy-
sis [17].
The present study was undertaken to investigate the util-
ity of  measuring the metabolite (mono-n-isobutyl phthalate, 
[MBP]) concentration of  DBP and the metabolite (mono-2-
ethylhexyl phthalate, [MEHP]; mono-(2-ethyl-5-hydroxyhexyl 
phthalate, [MEHHP]; mono-(2-ethyl-5-oxohexyl) phthalate, 
[MEOHP]) concentrations of  DEHP in serum and urine 
samples as an indicator of  occupational exposure to those 
phthalates by use of column-switching high-performance liquid 
chromatography tandem mass spectrometry (LC-MS/MS).
Materials and Methods 
Chemicals 
MBP, MEHP, MEHHP, and MEOHP were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). 13C4-MBP, 
13C4-MEHP, 
13C4-MEHHP, and 
13C4-MEOHP were purchased from Cam-
bridge Isotopes Laboratories (Cambridge, MA, USA). HPLC-
grade acetonitrile, water and all other chemicals were obtained 
from Honeywell Burdick & Jackson (Morristown, NJ, USA). 
Instruments and chromatographic conditions 
The analyses for measuring phthalate metabolites in urine and 
serum were performed on a Nanospace SI-2 high-performance 
liquid chromatography (Shiseido, Tokyo, Japan) with an API 
4000 triple quadrupole tandem mass spectrometer (Applied 
Biosystems, Foster City, CA, USA). On-line clean-up and 
separation of  phthalate monoesters was accomplished by 
the switching-column technique with a pretreatment column 
(Shisido MF C8, 50 × 4.6 mm, 5 μm), trap column (Imtackt 
Cadenza CD C18, 30 × 2.0 mm, 5 μm), and analytical column 
(Imtackt Cadenza CD C18, 75 × 2.0 mm, 3 μm). The pretreat-
ment column temperature was 37°C, the injection volume was 
10 μL, and the flow rates were 600 μL/min for the pretreatment 
and 200 μL/min for the analytical column. The mobile phases 
were 0.1% formic acid in water (A) and 0.1% formic acid in 
acetonitrile (B). Column switching was performed as follows: 
8.1 min for MBP, MEHHP and MEOHP trapping (mode A → 
mode B), 10.0 min (mode B → mode A), 14.8 min for MEHP 
trapping (mode A → mode B), and 15.3 min (mode B → mode 
A). Fig. 1 presents schemes of  the column switching proce-
Fig. 1. Schemes of switching column procedure. 1) A mode - online clean-up, 2) B mode - concentration to trap-column, 3) A mode - separation 
by analytical column and injection to MS/MS detector.
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dure. In mode A, the sample was loaded onto the pre-column 
controlled by autosampler pump A. While the pre-column was 
directed to waste, the sample was extracted on the pre-column. 
The matrices of compounds in the sample were removed while 
metabolites (MBP, MEHP, MEHHP, MEOHP) were retained 
on the pre-column. The extraction process was performed after 
closure of the on-line solid phase extraction. When the switch-
ing valve was changed to mode B, the pre-column was connect-
ed to a trap column. During this process all of the metabolites 
were retained on the trap column. After the metabolites were 
retained on the trap column, mode B changed into mode A 
again. Metabolites on the trap column transferred to an analyti-
cal column and the effluent from the analytical column was di-
rected to the MS/MS. Determination of phthalate metabolites 
was accomplished by electrospray ionization in the negative 
mode with spray ion voltage (-4,500 V), nitrogen nebulizer gas 
pressure (GS1 40 psi, GS2 60 psi), nitrogen curtain gas pres-
sure (15 psi), capillary temperature (400°C), and collisionally-
activated dissociation (CAD, 7). The parent ion (m/z), product 
ion (m/z), declustering potential (eV), and collision energy 
(eV) of each phthalate monoester were as follows: 221/149/-
48/-18 (MBP), 225/151/-48/-16 (13C4-MBP), 277/134/-55/-
21 (MEHP), 281/137/-55/-22 (13C4-MEHP), 293/121/-60/-23 
(MEHHP), 297/145/-75/-20 (13C4-MEHHP), 291/121/-55/-
24 (MEOHP), and 295/124/-55/-24 (13C4-MEOHP).
Standard solutions and sample preparation 
Working solutions of  standards (MBP, MEHP, MEHHP, 
MEOHP) and internal standards (13C4-MBP, 
13C4-MEHP, 
13C4-
MEHHP, 13C4-MEOHP) were made up at a concentration of 
1.0 mg/mL in acetonitrile. From the working solution of the 
analytes, calibration standards were prepared by spiking pooled 
serum and urine from 322 persons (elementary school: 60, 
middle and high school: 62, adult: 139, and old: 61) from the 
general population in Kyunggi province. 
The ages of  the sampled persons ranged from 8 to 65. 
These spot serum and urine samples were pooled, frozen at 
-20°C, and thawed at room temperature and vortex mixed be-
fore use. The non-spiked pooled serum and urine was used as 
a blank. The background concentration levels of metabolites in 
the pooled serum were 3.3 ng/mL (MBP), 3.9 ng/mL (MEHP), 
0.3 ng/mL (MEHHP), and 0.4 ng/mL (MEOHP). The back-
ground concentration levels of metabolites in the pooled urine 
were 7.2 ng/mL (MBP), 6.2 ng/mL (MEHP), 17.0 ng/mL 
(MEHHP), and 16.6 ng/mL (MEOHP). Additionally, a blank 
value consisting of water was included in every analytical se-
ries. The 0.5 mL aliquots of  spiked serum and urine sample 
were transferred to 1.5 mL glass screw-cap vials. Then, 10 μL 
of  each internal standard, 10 μL of  β-glucuronidase (Roche 
Diagnostics, IN, USA), and 100 μL of 1 M ammonium acetate 
were added to the samples. The samples were mixed gently and 
incubated at 37°C for 2 h. After a 10 min sonication, the sam-
ples were diluted two times with acetonitrile, and vortex mixed 
and centrifuged at 5,000 g for 10 min. The supernatant was 
filtered with a syringe filter (Nylon 0.2 μm, Whatman, Kent, 
UK). A 100 μL aliquot was then injected into the LC-MS/MS 
system for quantitative analysis. Fifty healthy male volunteers 
were included in this study. The study protocol was approved 
by the Ethics Committee of Yongin University and written in-
formed consent was obtained from the volunteers. 
Table 1. LOD and LOQ of phthalate metabolites in serum and urine samples
Matrix Metabolites LOD (ng/mL) LOQ (ng/mL) Concentration range (μg/mL) r value SE Slope RSD
Serum MBP 0.67 2.02 0-3.76 0.9985 340.7 0.027
MEHP 0.24 0.73 0.9953 809.3 0.125
MEHHP 0.08 0.23 0.9703 180.9 0.048
MEOHP 0.14 0.43 0.9959 302.4 0.046
Urine MBP 1.05 3.15 0-0.47 0.9943 1,180.3 0.062
MEHP 0.22 0.67 0.9994 22.3 0.014
MEHHP 0.15 0.46 0.9998 483.5 0.010
MEOHP 0.16 0.49 0.9964 94.5 0.042
LOD: limit of detection, LOQ: limit of quantitation, r: correlation coefficient, SE: standard error, RSD: relatively standard deviation, MBP: mono-
n-isobutyl phthalate, MEHP: mono-2-ethylhexyl phthalate, MEHHP: mono-(2-ethyl-5-hydroxyhexyl) phthalate, MEOHP: mono-(2-ethyl-5-oxo-
hexyl) phthalate.
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Determination of limit of detection (LOD) and limit 
of quantitation (LOQ) 
Six low-level calibration standards including a blank were pre-
pared. The linear regression equation of the relation between 
the analyte amount and the detector response, and the standard 
error (Sy) of  this regression equation were obtained, and the 
LOD and LOQ were calculated through a method suggested by 
the National Institute for Occupational Safety and Health [18]. 
Determination of recovery 
The recovery was tested at three different levels (low, medium, 
and high concentration) as previously reported [19-21]. In those 
studies, the ranges of the mean concentration for DEHP urine 
metabolites (MEHP, MEHHP, MEOHP) and DBP urine me-
tabolite (MBP) in the general population were 4.23-182 ng/mL 
and 17.7-20.2 ng/mL, respectively. In the study of the Korean 
general population [22], the geometric mean concentration 
range of DBP and DEHP metabolites in urine and serum were 
11.0-31.1 ng/mL, and 0.4-5.7 ng/mL, respectively. We decided 
to use the three different levels of  low to high concentrations 
from those studies. Each set of six spiked samples was prepared 
at the three concentration levels. The recovery was calculated 
as the percentage recovery.
Determination of precision of the analytical procedure 
The precision of  the analytical procedure was measured as 
the pooled coefficient of  variations (CVs) determined from 
replicate analysis of standards within the range of low to high 
concentrations. The homogeneity of the CVs over this range of 
concentrations was ascertained using Bartlett’s test [23]. 
Results 
LOD and LOQ 
The retention times of MBP, MEHP, MEHHP, and MEOHP 
were 14.92 min, 7.05 min, 17.36 min, 14.19 min, and 14.50 
min, respectively. The relative standard deviations of the reten-
tion times were < 0.60%. As presented in Table 1, the LODs in 
Table 2. Recovery of phthalate metabolites in serum 
Metabolite
Spiking level, 
ng/sample
Recovery, %
Mean ± SD Range
MBP 2 120.5 ± 11.0 107.5-134.5
4 115.9 ± 16.0 96.5-135.3
8 126.5 ± 9.4 110.9-137.5
Total 123.0 ± 12.4 96.5-137.5
MEHP 2 104.8 ± 19.8 72.5-124.5
4 114.7 ± 13.0 96.5-130.5
8 103.5 ± 10.0 91.6-119.4
Total 107.7 ± 14.9 72.5-130.5
MEHHP 2 100.6 ± 9.7 85.5-112.0
4 112.7 ± 5.0 107.3-120.8
8 111.0 ± 8.7 101.9-124.3
Total 108.1 ± 9.3 85.5-124.3
MEOHP 2 88.1 ± 9.1 72.5-98.0
4 95.1 ± 9.8 86.8-110.0
8 95.4 ± 3.5 89.5-99.6
Total 92.9 ± 8.3 72.5-110.0
SD: standard deviation, MBP: mono-n-isobutyl phthalate, MEHP: 
mono-2-ethylhexyl phthalate, MEHHP: mono-(2-ethyl-5-hydroxyhex-
yl) phthalate, MEOHP: mono-(2-ethyl-5-oxohexyl) phthalate.
Number of samples per level, n = 6.
Table 3. Recovery of phthalate metabolites in urine 
Metabolite
Spiking level, 
ng/sample
Recovery, %
Mean ± SD Range
MBP 8 103.0 ± 4.4 96.5-109.0
16 99.2 ± 4.0 94.6-106.0
32 97.9 ± 4.5 89.7-101.8
Total 100.0 ± 4.6 89.7-106.0
MEHP 4 96.8 ± 3.3 90.8-100.2
8 99.1 ± 4.2 93.3-105.5
16 97.0 ± 4.7 89.7-101.9
Total 97.6 ± 4.0 89.7-105.5
MEHHP 12 98.5 ± 5.0 93.0-104.6
24 103.9 ± 4.8 98.7-112.2
48 104.3 ± 3.3 99.0-108.9
Total 102.1 ± 5.0 93.0-112.2
MEOHP 65 102.4 ± 5.9 97.2-112.8
130 97.9 ± 6.7 87.4-104.7
260 98.3 ± 4.8 91.0-103.7
Total 99.5 ± 5.9 87.4-112.8
SD: standard deviation, MBP: mono-n-isobutyl phthalate, MEHP: 
mono-2-ethylhexyl phthalate, MEHHP: mono-(2-ethyl-5-hydroxyhex-
yl) phthalate, MEOHP: mono-(2-ethyl-5-oxohexyl) phthalate.
Number of samples per level, n = 6.
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serum were 0.67 ng/mL (MBP), 0.24 ng/mL (MEHP), 0.08 
ng/mL (MEHHP), and 0.14 ng/mL (MEOHP); the LODs in 
urine were 1.05 ng/mL (MBP), 0.22 ng/mL (MEHP), 0.15 
ng/mL (MEHHP), and 0.16 ng/mL (MEOHP). The LOQs in 
serum were 2.02 ng/mL (MBP), 0.73 ng/mL (MEHP), 0.23 
ng/mL (MEHHP), and 0.43 ng/mL (MEOHP); the LOQs in 
urine were 3.15 ng/mL (MBP), 0.67 ng/mL (MEHP), 0.46 
ng/mL (MEHHP), and 0.49 ng/mL (MEOHP).
Recovery 
Table 2 shows the results of the recovery test performed under 
three different serum metabolite levels (2-8 ng/sample). The 
recovery of MBP, MEHP, MEHHP, and MEOHP were 123.0 
± 12.4% (range: 96.5-137.5%), 107.7 ± 14.9% (72.5-130.5%), 
108.1 ± 9.3% (range: 85.5-124.3%), and 92.9 ± 8.3% (range: 
72.5-110.0%), respectively. The results of the recovery test for 
metabolites in urine samples are summarized in Table 3. The 
total mean recovery of each metabolite under the three differ-
ent levels was 97.6-102.1%. 
Precision of analytical procedure 
Table 4 shows the precision of the column-switching LC-MS/
MS method for analysis of the metabolites in serum and urine 
sample at three different concentration levels. There were no 
significant differences between the variances with 95% con-
fidence based on Bartlett’s test. As presented in Table 4, the 
pooled CVs for all three levels of  the serum samples were 
0.071 (MBP), 0.130 (MEHP), 0.078 (MEHHP), and 0.079 
(MEOHP); the pooled CVs in urine samples were 0.035 (MBP), 
0.030 (MEHP), 0.050 (MEHHP), and 0.044 (MEOHP). The 
pooled CVs of urine metabolites at the three levels were signifi-
cantly lower than those of the serum metabolites (p = 0.018, 
Fig. 2), demonstrating reproducibility of this method over vari-
ous concentrations in urine metabolites was much better than 
those of the serum samples.  
Table 4. Precision of the column-switching HPLC-MS-MS method
Metabolites
Serum Urine
Level of metabolite, 
ng/sample
CV
Level of metabolite, 
ng/sample
CV
MBP 2 0.075     8 0.051
4 0.073   16 0.034
8 0.064   32 0.010
Pooled 0.071 Pooled 0.035
MEHP 2 0.091     4 0.035
4 0.158     8 0.036
8 0.132   16 0.016
Pooled 0.130 Pooled 0.030
MEHHP 2 0.096   12 0.067
4 0.083   24 0.035
8 0.050   48 0.042
Pooled 0.078 Pooled 0.050
MEOHP 2 0.096   65 0.071
4 0.077 130 0.018
8 0.061 260 0.022
Pooled 0.079 Pooled 0.044
HPLC-MS-MS: high-performance liquid chromatography tandem mass spectrometric, CV: coefficient variation, MBP: mono-n-isobutyl 
phthalate, MEHP: mono-2-ethylhexyl phthalate, MEHHP: mono-(2-ethyl-5-hydroxyhexyl) phthalate, MEOHP: mono-(2-ethyl-5-oxohexyl) phthal-
ate. 
Number of samples at each level, n = 6. 
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Discussion 
Two goals are routine in analytical method development and 
validation. The first goal is the circumvention of  extensive 
clean-up and concentration steps that could negatively affect 
method performance. The second goal is to achieve fast run-
times that allow efficient use of the analytical instrument. The 
column switching techniques applied in this study met these 
requirements in a state-of-the art technique that permitted the 
effective subsequent transfer, separation, and quantification on 
the analytical column with LC-MS/MS.
Humans are exposed to phthalates by multiple routes, 
with the most likely route varying depending on if  one is in the 
general population or a worker. In the case of the general popu-
lation, exposure can be oral through phthalate-contaminated 
food, water, and other liquids, or dermal by cosmetics and oth-
er personal care products. But, the main exposure of workers is 
inhalation and dermal. In contrast, almost all rodent toxicologi-
cal studies to date have relied on oral exposure. Therefore, these 
rodent studies may not reflect toxicity of phthalates to humans 
who are exposed via other routes. 
Traditional epidemiological methods of  exposure as-
sessment, such as questionnaires, medical records, and air 
monitoring that are used for multiple exposure routes, are of 
limited usefulness in determining individual exposure. Instead, 
biomarkers of  exposure are preferred. But the occupational 
biological exposure standard for phthalates (DBP, and DEHP) 
is not yet established. 
Phthalates and their metabolites have been measured in 
many body fluids and matrices, including urine, serum, saliva, 
seminal fluid, breast milk, amniotic fluid, and even placenta [24]. 
But urine and serum are the preferred matrices for phthalate 
determination in humans [25,26]. However, little published 
data exists on adverse workplace health outcomes and phthal-
ate exposure assessment using biomarkers.
The LODs (0.08-0.67 ng/mL) of  serum metabolites for 
DBP and DEHP were slightly lower than those (0.15-1.05 ng/
mL) of  urine metabolites. The LODs of  MEHP, MEHHP, 
and MEOHP in serum and urine matrices by this analytical 
method are approximately 10-fold lower than the LODs of 
those metabolites in the same matrices by LC-MS/MS without 
column switching [15,27]. These levels are sufficient to evaluate 
concentrations of phthalate metabolites for not only industrial 
workers but also for the general population [5,19]. 
Because of  the rapid metabolism of  phthalates, urinary 
metabolite levels are typically higher than serum metabolite 
levels, as well as those of  any other matrix. So, we carried 
out recovery testing of  the metabolites in the representative 
concentration levels of  each matrix. The minimum recovery 
of metabolites from urinary samples in this analytical method 
should be greater than 87%. But the minimum recovery of se-
rum metabolites (MEHP, MEOHP) should be lower than 75%. 
Also, the recovery range (72-138%) of  phthalate metabolites 
in serum was much greater than the recovery range (87-113%) 
of urinary phthalate metabolites, meaning that determination 
of urinary metabolites should be more accurate. As shown in 
Table 4 and Fig. 1, the precision of analytical procedure for uri-
nary metabolites determination was more acceptable, with this 
method demonstrating very good repeatability. 
In conclusion, our results show that the column switching 
LC-MS/MS method for the determination of  phthalate me-
tabolites is a very sensitive, accurate, and time saving analytical 
method. Also, for measurement with more acceptable accuracy 
and precision, urinary phthalate metabolite measurements as 
biomarkers may be more relevant in studies of phthalate expo-
sure and adverse health outcomes.
The limitation of this study was that the urine and serum 
samples that came from the general population were used. 
Those samples could not sufficiently represent the samples 
from occupationally exposed workers. However, we thought the 
phthalate metabolites level of occupationally exposed workers 
could be higher than those of the general population. And even 
though we used samples from the general population, many 
of  those in the general population had various occupational 
jobs. We thought that this analytical method could be used in 
the determination of phthalate metabolites for occupationally 
exposed workers. 
Fig. 2. Distribution of precision results in analyzing the metabolites 
in serum and urin samples at three different levels.  MBP: mono-n-
isobutyl phthalate, MEHP: mono-2-ethylhexyl phthalate, MEHHP: 
mono-(2-ethyl-5-hydroxyhexyl) phthalate, MEOHP: mono-(2-ethyl-5-
oxohexyl) phthalate.
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